or Try an Advanced Search...

    Hematologic Malignancies Stocks List

    Symbol Grade Name % Change
    AFMD F Affimed Therapeutics B.V. 0.00
    TCRX F TScan Therapeutics, Inc. 0.00
    APTO F Aptose Biosciences, Inc. 0.00
    HOWL F Werewolf Therapeutics, Inc. 0.00
    FATE F Fate Therapeutics, Inc. 0.00
    INMB F INmune Bio Inc. 0.00
    CLLS F Cellectis S.A. 0.00
    CRBU D Caribou Biosciences, Inc. 0.00
    SLS D SELLAS Life Sciences Group, Inc. 0.00
    KYMR D Kymera Therapeutics, Inc. 0.00
    View As Page of Charts
    Related Industries: Biotechnology
    Related Stock Lists: Solid Tumors Biopharmaceutical Cancer Medicine Biotechnology Clinical Medicine Tumors Of The Hematopoietic And Lymphoid Tissues Acute Myeloid Leukemia CD19 Immune System Life Sciences Blastoma Cancer Immunotherapy Cancer Treatment Chronic Lymphocytic Leukemia Glioblastoma Immunology Immunotherapies Immunotherapy Leukemia

    Related ETFs - A few ETFs which own one or more of the above listed Hematologic Malignancies stocks.

    Symbol Grade Name Weight
    CNCR F Loncar Cancer Immunotherapy ETF 3.66
    WDNA D WisdomTree BioRevolution Fund 1.68
    PTH D Invesco DWA Healthcare Momentum ETF 1.63
    SURI D Simplify Exchange Traded Funds Simplify Propel Opportunities ETF 1.37
    HAPS B Harbor Corporate Culture Small Cap ETF 1.32
    View all Hematologic Malignancies ETFs...
    Compare ETFs
    Compare PTH to HAPS Compare WDNA to PTH Compare WDNA to SURI

        Hematologic Malignancies Stocks Recent News

        Date Stock Title
        Nov 22 APTO Aptose Biosciences Inc. Announces Pricing of $8 Million Public Offering
        Nov 20 FATE Fate Therapeutics: FT819 Finding Bodes Well For Future Of SLE Treatment Options
        Nov 20 CRBU Caribou Biosciences to Participate in Upcoming Investor Conferences
        Nov 20 HOWL Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference
        Nov 20 APTO Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet Therapy
        Nov 19 AFMD Is Affimed N.V. (AFMD) the Best German Stock to Buy Now?
        Nov 19 FATE Wall Street Breakfast Podcast: Fate Therapeutics Rises On Lupus Drug Data
        Nov 18 FATE Fate Therapeutics Shares Rise After 'Promising' Lupus Treatment Results
        Nov 18 FATE Fate stock rallies 37% on positive Phase 1 data for FT819, FT522
        Nov 18 FATE Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence
        Nov 18 FATE Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR Convergence
        Nov 16 SLS We're A Little Worried About SELLAS Life Sciences Group's (NASDAQ:SLS) Cash Burn Rate
        Related Industries: Biotechnology
        Related Stock Lists: Solid Tumors Biopharmaceutical Cancer Medicine Biotechnology Clinical Medicine Tumors Of The Hematopoietic And Lymphoid Tissues Acute Myeloid Leukemia CD19 Immune System Life Sciences Blastoma Cancer Immunotherapy Cancer Treatment Chronic Lymphocytic Leukemia Glioblastoma Immunology Immunotherapies Immunotherapy Leukemia
        Hematologic Malignancies

        Hematologic malignancies are cancers of the blood, bone marrow, and lymphatic system. These cancers can affect the production and function of blood cells, leading to a variety of symptoms and complications. Common types of hematologic malignancies include leukemia, lymphoma, and multiple myeloma. Treatment for hematologic malignancies may include chemotherapy, radiation therapy, stem cell transplant, and targeted therapy.

        Browse All Tags